Karolinska Development Past Earnings Performance
Past criteria checks 0/6
Karolinska Development's earnings have been declining at an average annual rate of -3.2%, while the Pharmaceuticals industry saw earnings growing at 8.5% annually. Revenues have been declining at an average rate of 13.2% per year.
Key information
-3.2%
Earnings growth rate
-19.4%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | -13.2% |
| Return on equity | -5.7% |
| Net Margin | -3,316.9% |
| Next Earnings Update | 18 Nov 2022 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Karolinska Development makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 22 | 2 | -72 | 29 | 0 |
| 31 Mar 22 | 2 | 166 | 28 | 0 |
| 31 Dec 21 | 2 | 171 | 24 | 0 |
| 30 Sep 21 | 2 | 276 | 21 | 0 |
| 30 Jun 21 | 2 | 108 | 24 | 0 |
| 31 Mar 21 | 2 | -106 | 24 | 0 |
| 31 Dec 20 | 3 | -207 | 24 | 0 |
| 30 Sep 20 | 3 | 35 | 26 | 0 |
| 30 Jun 20 | 3 | 190 | 23 | 0 |
| 31 Mar 20 | 4 | 195 | 24 | 0 |
| 31 Dec 19 | 3 | 303 | 24 | 0 |
| 30 Sep 19 | 4 | -11 | 21 | 0 |
| 30 Jun 19 | 4 | 8 | 20 | 0 |
| 31 Mar 19 | 3 | 32 | 16 | 0 |
| 31 Dec 18 | 3 | 31 | 16 | 0 |
| 30 Sep 18 | 3 | 48 | 20 | 0 |
| 30 Jun 18 | 3 | 238 | 22 | 0 |
| 31 Mar 18 | 3 | 185 | 24 | 0 |
| 31 Dec 17 | 2 | 180 | 25 | 0 |
| 30 Sep 17 | 5 | 125 | 23 | 0 |
| 30 Jun 17 | 5 | -87 | 22 | 0 |
| 31 Mar 17 | 5 | -142 | 20 | 0 |
| 31 Dec 16 | 5 | -217 | 19 | 0 |
| 30 Sep 16 | 2 | -315 | 24 | 0 |
| 30 Jun 16 | 2 | -325 | 25 | 0 |
| 31 Mar 16 | 3 | -904 | 29 | 0 |
| 31 Dec 15 | 3 | -1,055 | 33 | 0 |
| 30 Sep 15 | 4 | -980 | 41 | 0 |
Quality Earnings: KDEV.F is currently unprofitable.
Growing Profit Margin: KDEV.F is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: KDEV.F is unprofitable, and losses have increased over the past 5 years at a rate of 3.2% per year.
Accelerating Growth: Unable to compare KDEV.F's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: KDEV.F is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-17.3%).
Return on Equity
High ROE: KDEV.F has a negative Return on Equity (-5.65%), as it is currently unprofitable.